There are many forms of Multiple Myeloma. Genetic profiling of the cancer helps in determining the best treatment strategy. Click through the website to see how the MMprofilerTM with the SKY92 algorithm can help in daily clinical practice to indentify patients that progress faster or how the MMprofilerTM with the SKY92 algorithm can help in clinical trials to distinguish between three different patient subpopulations.

Multiple Myeloma

Multiple Myeloma is an uncontrolled growth of malignant plasma cells in the bone marrow. An estimated 114,000 people around the world are diagnosed with multiple myeloma annually, and the disease represents 0.8% of all cancers globally.

read more


MM survival rates can range from under 2 years to up to 20 years. Without knowing each patient's risk profile, it can be challenging to determine which treatment plan to start. MMprofilerTM with SKY92 helps to address this challenge.

read more


Health care professionals and researchers can find more documentation and literature references here. Or you can get in contact with SkylineDx with the possibility to plan a visit to the SkylineDx lab in Rotterdam. 

read more